We’re not generally in the awards business here at STAT (with a few exceptions), but as we reflected back on this year, we felt one company stood out for rebounding from tough times. So we hereby anoint Juno Therapeutics (JUNO) as the comeback company of the year.
Few have forgotten Juno’s worst moment: the deaths of five patients with advanced acute lymphoblastic leukemia who were being treated with the company’s experimental CAR-T therapy known as JCAR015. The Food and Drug Administration quickly put the JCAR015 program on clinical hold; later, the study was scuttled entirely.
About the Author Reprints
